Stocklore

Zimmer Biomet Holdings, Inc. (ZBH)

Biotech & Health · US stock

What changed in recent filings

  • Institutions — 8 new · 2 added13F · as of end of 2026 Q2

What changed in recent SEC filings — factual, not a buy/sell recommendation.

Institutions holding Zimmer Biomet Holdings, Inc.

How many of the institutions we track reported holding this stock, quarter by quarter.

max 10
2019 Q1 · 22019 Q2 · 32019 Q3 · 02019 Q4 · 12020 Q1 · 32020 Q2 · 42020 Q3 · 52020 Q4 · 62021 Q1 · 52021 Q2 · 62021 Q3 · 72021 Q4 · 52022 Q1 · 32022 Q2 · 32022 Q3 · 32022 Q4 · 32023 Q1 · 52023 Q2 · 42023 Q3 · 42023 Q4 · 32024 Q1 · 32024 Q2 · 32024 Q3 · 32024 Q4 · 32025 Q1 · 42025 Q2 · 32025 Q3 · 42025 Q4 · 52026 Q1 · 22026 Q2 · 10
19 Q122 Q326 Q2

2019 Q1: 2 → 2026 Q2: 10 institutions

Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.

Which institutions hold Zimmer Biomet Holdings, Inc.

Institutions we track that reported holding this stock in their most recent 13F.

  • Bridgewater Associates0.01% of portfolio · since 2020 Q3
  • Dodge & Cox1.09% of portfolio · since 2022 Q1
  • Tudor Investment CorpNew this quarter0.01% of portfolio · since 2026 Q2
  • Point72 Asset ManagementNew this quarter0.08% of portfolio · since 2026 Q2
  • Moore Capital ManagementNew this quarter0.25% of portfolio · since 2026 Q2
  • PRIMECAP Management0.19% of portfolio · held as of 2026 Q2 or earlier
  • Blackstoneunder 0.01% of portfolio · held as of 2026 Q2 or earlier
  • National Pension Service (Korea)0.01% of portfolio · held as of 2026 Q2 or earlier
  • Harris Associates (Oakmark)1.45% of portfolio · held as of 2026 Q2 or earlier
  • Capital World Investorsunder 0.01% of portfolio · held as of 2026 Q2 or earlier

Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.

Company overview

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.

What is the Biotech & Health sector?

Pharma, biotech, and medical devices. Driven by trial-result events.

Zimmer Biomet Holdings, Inc. is classified under the Biotech & Health sector. See peers below.

ETFs holding Zimmer Biomet Holdings, Inc.

Per SEC N-PORT · 2026-06-30 · by weight · factual

XLVState Street(R) Health Care Select Sector SPDR(R) ETF
0.29%
RSPInvesco S&P 500 Equal Weight ETF
0.17%
VTVVANGUARD VALUE INDEX FUND
0.03%
SPY
0.03%
VOOVANGUARD 500 INDEX FUND
0.03%
IVViShares Core S&P 500 ETF
0.03%
VTIVANGUARD TOTAL STOCK MARKET INDEX FUND
0.02%
ITOTiShares Core S&P Total U.S. Stock Market ETF
0.02%

ZBH on Stocklore

  • Revenue by segmentsegment weights verified from SEC filings, YoY changes, growth drivers and concentration
  • Financials & earnings quality6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
  • 13F institutional holdingsholdings and weight changes of major institutions (45-day delay)
  • Sector-relative metricsValuation and growth compared with the Biotech & Health average
See full ZBH analysis →

Peers · Biotech & Health

ZBH FAQ

What is Zimmer Biomet Holdings, Inc. (ZBH)?

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.

What sector is Zimmer Biomet Holdings, Inc. in?

Zimmer Biomet Holdings, Inc. is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.

Where can I analyze Zimmer Biomet Holdings, Inc. (ZBH) stock?

On Stocklore you can see ZBH's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.

Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.

Not an investment adviser and not personalized investment advice; not a discretionary management service. No trade recommendations, no target prices, no execution or brokerage. We do not recommend or guarantee any purchase, sale, or returns. Investment decisions and their outcomes are your own.

Stocklore · CEO Lee Seung-jae · Business reg. no. 764-36-01607 · E-commerce permit 2026-Jeonju Wansan-0476 · Tel +82-70-7954-4939 · S120, Rm 302, 3F, 21 Jungsanjungang-ro, Wansan-gu, Jeonju, Jeonbuk, Korea